Abstract
Mutated isoforms of CCDC6 sensitize HGSOC cells to the PARPi olaparib alone or in combination with cisplatin. A–D, Drug sensitivity to olaparib or cisplatin has been evaluated by cell viability assay (CellTiter 96 Aqueous One Solution assay, Promega) in OVCAR3 and OV90 cell lines transfected with the myc-CCDC6 mutated isoforms L217P, A226S, and P442S or with the EV and exposed to the drug for 144 hours. The drug sensitivity is expressed as IC50 values. Statistical significance was verified by two-way ANOVA (*, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001). E, The CI values according to the 1:2 concentration ratio of cisplatin and olaparib are shown (CI < 1, CI = 1, and CI > 1 indicate synergism, additive effect, and antagonism, respectively).